Salvianolic acid b complex and its preparation and application

A technology of salvianolic acid and compound, applied in the field of salvianolic acid B complex and its preparation and application, can solve the problems of pesticide residues, adverse reactions, unstable content of active ingredients, etc., and achieve the effect of promoting angiogenesis

Active Publication Date: 2022-05-17
CHIATAI QINGCHUNBAO PHARMA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] However, the current compound preparations of Salvia miltiorrhiza and Chuanxiong are difficult to control due to the shortcomings of the extraction process and the characteristics of the Chinese medicinal materials themselves.
The original drug extract contains unpredictable impurities, which are likely to cause adverse reactions, and there are problems of heavy metals and pesticide residues
The shortcomings of unstable content of active ingredients and impurities lead to hidden dangers of drug safety in its compound preparations, especially injections

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Salvianolic acid b complex and its preparation and application
  • Salvianolic acid b complex and its preparation and application
  • Salvianolic acid b complex and its preparation and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] 1. Experimental materials

[0040] Ponatinib was purchased from Selleck Biotechnology Co., Ltd., USA.

[0041] Transparent 96-well cell culture plates were purchased from Wuxi Ness Biotechnology Co., Ltd., NEST brand.

[0042] E3 buffer: every 1000L deionized water contains 292.5g NaCl, 12.67g KCl, CaCl 2 36.63g and MgSO 4 39.6 g, adjusted to pH 7.2 with 1M aqueous sodium bicarbonate solution.

[0043] Juvenile fish culture solution: E3 buffer containing 200 μM 1-phenyl-2-thiourea (PTU), the purpose is to inhibit the production of melanin and facilitate subsequent experimental observation.

[0044] The transgenic zebrafish Tg (Fli:eGFP), which labeled endothelial cells with green fluorescent protein, was purchased from the zebrafish sub-platform of the public technology platform of Zhejiang University.

[0045] 2. Experiment

[0046] Drug grouping: volume concentration 0.1% DMSO control (control) group, ponatinib (model) 10 μM group, ponatinib 10 μM + salvianolic ...

Embodiment 2

[0051] Change the drugs of each group in Example 1 to: 0.1% DMSO control group, ponatinib (model) 10 μ M group, and different administration groups based on 10 μ M ponatinib modeling, including: positive drug vascular endothelial growth Factor VEGF 100ng / ml group, salvianolic acid B 100μg / ml group, danshensu 100μg / ml group, rosmarinic acid 100μg / ml group, ferulic acid 100μg / ml group, ligustalactone I 100μg / ml group, Ferulic acid 50 μg / ml + salvianolic acid B 50 μg / ml group, ferulic acid 50 μg / ml + rosmarinic acid 50 μg / ml group, ferulic acid 50 μg / ml + danshensu 50 μg / ml group, chuanxiong lactone I 50 μg / ml ml+rosmarinic acid 50 μg / ml group, ligustonin I 50 μg / ml+danshensu 50 μg / ml group, lisantrolactone I 50 μg / ml+salvianolic acid B 50 μg / ml group, other operations were the same as in Example 1, the results See Figure 5 . Figure 5 It shows that in addition to the salvianolic acid B (100 μg / ml) in Example 1 has the effect of promoting angiogenesis, the main compound Danshe...

Embodiment 3

[0053] Change each group of drugs in Example 1 to: 0.1% DMSO control group, ponatinib (model) 10 μ M group, and different administration groups on the basis of 10 μ M ponatinib modeling, including: ferulic acid 100 μ g / ml group, salvianolic acid B 100 μg / ml group, ferulic acid 50 μg / ml + salvianolic acid B 50 μg / ml group (1:1), ferulic acid 33 μg / ml + salvianolic acid B 67 μg / ml group (1:2 ), other operations are the same as in Example 1, and the results are shown in Figure 6 . Figure 6 It shows that the compatibility group of 50μg / ml ferulic acid and 50μg / ml salvianolic acid B, and the compatibility group of 33μg / ml ferulic acid and 67μg / ml salvianolic acid B have synergistic effect, but the compatibility effect of 1:1 group is better than that of 1 : 2 sets of compatibility effects. **, P<0.01.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of medicine, in particular to a salvianolic acid B complex and its preparation and application. The salvianolic acid B complex includes salvianolic acid B and ferulic acid, and the mass ratio of salvianolic acid B and ferulic acid is 1-2:1. Salvianolic acid B works synergistically with ferulic acid to promote angiogenesis, thereby treating ischemic heart disease with decreased angiogenesis.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a salvianolic acid B complex and its preparation and application. Background technique [0002] Angiogenesis is a biological process in which a new capillary network is further formed on the basis of the existing vascular network structure through the proliferation, migration, sprouting, vascular division and branching of vascular endothelial cells, so that its function and local needs are adapted. Angiogenesis plays an important role in physiological and pathological processes such as embryonic development, wound healing, periodic proliferation of endometrium, tumors, and proliferative retinopathy. By improving and regulating the unbalanced process of angiogenesis in the body, the purpose of treating corresponding diseases can be achieved. [0003] The formation and development of new blood vessels is also a potentially important therapeutic approach for treating vital organs ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/343A61K31/192A61P9/10A61P9/00A61P9/04
CPCA61K31/343A61K31/192A61P9/10A61P9/00A61P9/04A61K2300/00
Inventor 王毅赵璐赵滢
Owner CHIATAI QINGCHUNBAO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap